Discover opportunities months before the RFP drops
Learn more →Retrieving contract details... Hang tight!
See what competitors charge and their contract structure
Spot renewal opportunities 6-12 months before expiration
Analyze buyer's purchasing history and vendor preferences
Track expiration dates across all your target accounts
Reach decision-makers before renewal with competitive intel
Our customers win 3x more contract renewals and replacements
Premium
Clean & enrich your CRM automatically
Premium
Get complete source documentation & analysis
This contract includes 1 purchase order from Aug 23, 2023 to Aug 23, 2023
| Buyer | Vendor | Issued Date | Quantity |
|---|---|---|---|
| National Institutes of Health Niaid | Johns Hopkins University | Aug 23, 2023 | 1 |
Full Purchase Intelligence Available
Get complete pricing, descriptions, and financial details for all 1 purchase orders
Unlock Full Details →See what competitors charge and their contract structure
Spot renewal opportunities 6-12 months before expiration
Analyze buyer's purchasing history and vendor preferences
Track expiration dates across all your target accounts
Reach decision-makers before renewal with competitive intel
Our customers win 3x more contract renewals and replacements
No public files available for this contract.
Contract documentation may be available through official government sources or agency portals. Starbridge can help you track down and retrieve these files.
PHASE I RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY, AND PHARMACOKINETICS
Effective Date
Jul 15, 2024
Expires
Effective: Jul 15, 2024
PHASE I RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY, AND PHARMACOKINETICS
ActiveTHE CONTRACTOR SHALL COORDINATE, MAINTAIN AND MANAGE NICHD PARTICIPATING SITES FOR IMPAACT 2041: PHASE I/II STUDY OF THE PHARMACOKINETICS AND SAFETY OF GLECAPREVIR/PIBRENTASVIR INITIATED IN PREGNANCY IN PEOPLE WITH HEPATITIS C WITH AND WITHOUT HIV.
Effective Date
Mar 7, 2025
Expires
THE CONTRACTOR SHALL COORDINATE, MAINTAIN AND MANAGE NICHD PARTICIPATING SITES FOR IMPAACT 2041: PHASE I/II STUDY OF THE PHARMACOKINETICS AND SAFETY OF GLECAPREVIR/PIBRENTASVIR INITIATED IN PREGNANCY IN PEOPLE WITH HEPATITIS C WITH AND WITHOUT HIV.
ActiveNICHD: R&D: TO EVALUATE IN OBESE AND NON-OBESE WOMEN THE PHARMACOKINETICS (PK), PHARMACODYNAMIC (PD) EFFECTS, SAFETY, AND CONTRACEPTIVE EFFICACY OF LEVONORGESTREL BUTANOATE (LB) FORMULATED AS A LONG-ACTING INJECTABLE: NON-SEVERABLE
Effective Date
Jul 23, 2025
Expires
NICHD: R&D: TO EVALUATE IN OBESE AND NON-OBESE WOMEN THE PHARMACOKINETICS (PK), PHARMACODYNAMIC (PD) EFFECTS, SAFETY, AND CONTRACEPTIVE EFFICACY OF LEVONORGESTREL BUTANOATE (LB) FORMULATED AS A LONG-ACTING INJECTABLE: NON-SEVERABLE
ActiveTHE PURPOSE OF THIS TO IS TO RECRUIT, FOLLOW, AND COMPLETE THE "OPEN-LABEL, PHASE I STUDY OF THE SAFETY AND PHARMACOKINETICS OF PGT121.414.LS ALONE AND IN COMBINATION WITH VRC07-523LS IN INFANTS EXPOSED TO HIV-1."
Effective Date
Feb 28, 2024
Expires
THE PURPOSE OF THIS TO IS TO RECRUIT, FOLLOW, AND COMPLETE THE "OPEN-LABEL, PHASE I STUDY OF THE SAFETY AND PHARMACOKINETICS OF PGT121.414.LS ALONE AND IN COMBINATION WITH VRC07-523LS IN INFANTS EXPOSED TO HIV-1."
ActiveSee who's winning contracts, track spending trends, and identify your best opportunities before your competition.
Schedule Your Demo →Premium
Clean & enrich your CRM automatically
Premium
Get complete source documentation & analysis